儿童BRAF-V600E胶质瘤标准治疗诱导衰老并增敏BCL-xL抑制
该临床前研究在儿童BRAF-V600E低级别胶质瘤模型中探究治疗诱导衰老对复发的作用。Trametinib在BT-40体内诱导衰老表型,Navitoclax经抑制BCL-xL清除衰老细胞;联合治疗减少停药后肿瘤再生长并改善生存。
要点
- 儿童BRAF-V600E胶质瘤标准治疗可诱导肿瘤细胞衰老。
- Navitoclax经抑制BCL-xL清除衰老BT-40细胞。
- Trametinib联合Navitoclax减少停药后复发并改善生存。
核心结论
- Navitoclax增强Trametinib抗肿瘤疗效并限制停药后肿瘤复发。
- 标准治疗可使部分BRAF-V600E胶质瘤细胞进入衰老状态并改变肿瘤环境。
- 衰老肿瘤细胞可被senolytics清除,联合策略在小鼠模型中改善生存。
研究设计与样本
- 儿童低级别胶质瘤临床前模型,体外分析或原位移植入小鼠。
- 治疗药物包括Dabrafenib、Trametinib、Tovorafenib或Vinblastine。
- 用分子和细胞学标志物评估衰老,用体外剂量反应和体内治疗研究评估senolytics敏感性。
主要发现
- Trametinib在BT-40体内诱导稳健衰老表型,伴衰老相关分泌表型激活和IBA-1阳性髓系细胞扩增。
- BT-40细胞经MAPK抑制剂和Vinblastine处理后在体外诱导衰老,表达BRAF-V600E的H9来源人神经干细胞亦观察到衰老。
- Navitoclax被鉴定为针对衰老BT-40细胞的有效senolytic,主要经抑制抗凋亡蛋白BCL-xL。
- 体内Trametinib联合Navitoclax清除衰老肿瘤细胞,显著减少停药后肿瘤再生长并改善生存。
临床怎么用
- 儿童BRAF-V600E胶质瘤治疗 withdrawal 后需关注肿瘤再生长,衰老细胞可能是复发来源。
- senolytics联合MAPK抑制剂策略值得进一步临床前和转化验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemo-, radio-, and targeted therapies can induce a stable growth arrest known as therapy-induced senescence (TIS), which may be therapeutically exploited using senolytic compounds that selectively eliminate senescent cells. Children with BRAF-V600E-driven brain tumours are commonly treated with low-dose chemotherapies and MAPK inhibitors, alone or in combination, often with good initial responses. However, a majority of patients experiences tumour regrowth following treatment withdrawal. Here, we investigate the contribution of TIS to treatment response and relapse, and assess the therapeutic potential of senolytics in preclinical models of paediatric BRAF-V600E glioma. METHODS: Preclinical models of paediatric low-grade glioma were analysed in vitro or following orthotopic transplantation into mice and treated with Dabrafenib, Trametinib, Tovorafenib or Vinblastine. Senescence was assessed using molecular and cytological markers. Sensitivity to senolytic compounds was evaluated using in vitro dose-response assays and in vivo treatment studies. RESULTS: Trametinib induced a robust senescent phenotype in BT-40 tumours in vivo, characterised by activation of a senescence-associated secretory phenotype and expansion of IBA-1-positive myeloid cells. In vitro, senescence was induced in BT-40 cells following treatment with MAPK inhibitors and Vinblastine, and was similarly observed in H9-derived human neural stem cells expressing BRAF-V600E. Navitoclax was identified as a potent senolytic against senescent BT-40 cells, primarily through inhibition of the anti-apoptotic protein BCL-xL. In vivo, combined Trametinib and Navitoclax treatment ablated senescent tumour cells, significantly reduced tumour regrowth after treatment withdrawal, and improved survival. CONCLUSIONS: These findings demonstrate that Navitoclax enhances Trametinib's anti-tumour efficacy and limits tumour relapse following treatment cessation. Children with BRAF-V600E gliomas can respond well to treatment, but tumours may return after therapy stops. We reveal that standard treatment can push some tumour cells into a state called cellular senescence, in which they stop growing but remain alive. These senescent cells release signals that alter the tumour environment and may contribute to tumour recurrence. Importantly, we found that senescent tumour cells can be eliminated using drugs called senolytics. We show that combining standard treatment with a senolytic approach prevents tumour regrowth and significantly improves survival in mouse models.
引用
- Guiho, Hamdi, Cooksley, et al. Standard treatment against paediatric BRAF-V600E glioma promotes senescence and sensitizes tumours to BCL-xL inhibition. Neuro Oncol. 2026. PMID: 42954328. doi:10.1093/neuonc/noag270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。